Abstract:8624 Background: Ensartinib is an oral tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK), which has shown systemic and central nervous system efficacy in ALK-positive non-small cell lung cancer (NSCLC) and superiority over crizotinib in the first-line setting. This single-arm phase-1b study evaluates the efficacy of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive advanced NSCLC. Methods: Patients were treated with 4 cycles of induction ensartinib, carboplatin, pemetrexed, and bevacizumab before receiving maintenance ensartinib with or without bevacizumab and/or pemetrexed until disease progression or intolerable toxicity. Prior treatment with ALK-targeting agents and the presence of asymptomatic brain metastases were allowed. The primary endpoints were to determine safety of ensartinib in combination with carboplatin, pemetrexed, and bevacizumab and to determine the recommend phase 2 dose of ensartinib in this combination. Results: Between June 22, 2021, and August 15, 2022, 6 patients were enrolled into the study and treated with at least one dose of ensartinib in combination with platinum-based chemotherapy and bevacizumab. All patients were included in safety and efficacy analyses. The median age was 54.7y, 3/6 were female, 5/6 were never smokers, the median ECOG was 1, and 3/6 had brain metastases at enrollment. Participants received a median of 2 prior lines of therapy (range 0-3) and 4/6 received prior ALK TKI therapy: 2/6 two prior ALK TKIs, 2/6 three prior ALK TKIs. As of 12/1/2022, the maximum severity adverse event (AE) was grade 2 in 1/6 patients, grade 3 in 4/6 patients, and grade 5 in 1/6 - a therapy unrelated bronchopulmonary hemorrhage. Ensartinib-related grade 1, 2, and 3 AEs occurred in 1/6, 3/6, and 2/6 respectively. Dose reductions from 225mg daily to 200mg daily occurred in 1/6 patients secondary to grade 3 transaminitis, which was subsequently well tolerated. 1/6 patients transitioned therapy after a treatment unrelated bowel perforation. The median time on trial was 9.6 months. 2/6 patients remained on treatment at time of censorship with trial durations of 22.6 and 15.8 months. 1/6 patients progressed and 2/6 patients died on treatment. Conclusions: Ensartinib in combination with platinum-based chemotherapy and bevacizumab had an acceptable safety profile and demonstrates clinical activity in treatment naïve and previously treated advanced ALK-positive NSCLC, including in patients treated with prior ALK-targeted therapies. Next phase study designs are currently being considered. Clinical trial information: 2020-0838.

First case report of ensartinib in a patient with metastatic ALK rearranged lung cancer with ALK I1171N mutation: a case report

Ensartinib is effective in the treatment of advanced non-small-cell lung cancer with MET amplification after multi-line ALK-TKIs resistance: a case report

Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report

Novel LINC01923 -anaplasticlymphoma kinase rearrangement identified in advanced lung adenocarcinoma with durable response to ensartinib: a case report

Neoadjuvant target therapy with ensartinib in lung adenocarcinoma with EML4-ALK fusion variant: a case report and literature review

A phase 1b study of ensartinib in combination with platinum-based chemotherapy and bevacizumab in ALK-positive non-small cell lung cancer (NSCLC).

STRN-ALK Fusion in Lung Adenocarcinoma with Brain Metastasis Responded Well to Ensartinib: A Case Report

RET rearrangement as a mechanism of resistance to ALK-TKI in non-small cell lung cancer patient with EML4-ALK fusion: A case report

Case report: ALK D1225N missense mutation in lung adenocarcinoma responds to tyrosine kinase inhibitors

Case Report: A rare case of non-small cell lung cancer with STRN-ALK fusion in a patient in very poor condition treated with first-line ensartinib

A novel secondary ALK gene mutation which resistant to second-generation TKIs: a case report and literature review

Case Report: Efficacy of ensartinib treatment in pulmonary inflammatory myofibroblastic tumor with a rare GCC2-ALK fusion

Case Report: Ensartinib for gastric epithelioid inflammatory myofibrosarcoma with STRN-ALK fusion

Primary Resistance to Alectinib in a Patient with STRN‐ALK‐positive Non‐small Cell Lung Cancer: A Case Report

ALK: a tyrosine kinase target for cancer therapy

Ensartinib (X-396) in ALK-positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.

Case report: Durable response of ensartinib targeting EML4-ALK fusion in osimertinib-resistant non-small cell lung cancer

Case Report: Heterogeneity of Resistance Mechanisms in Different Lesions Co-Mediate Acquired Resistance to First-Line Icotinib in EGFR Mutant Non-Small Cell Lung Cancer

[Expert consensus on ensartinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer].

ALK-tyrosine kinase inhibitor intrinsic resistance due to de novo MET-amplification in metastatic ALK-rearranged non-small cell lung cancer effectively treated by alectinib-crizotinib combination—case report

Ensartinib in the treatment of anaplastic lymphoma kinase‐positive locally advanced or metastatic patients with lung squamous or adenosquamous carcinoma: A real‐world, retrospective study